• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Metformin may improve survival for advanced lung adenocarcinoma patients with higher BMI and taking EGFR-TKI therapy

byJamie ParkandSamuel Chan
January 24, 2022
in Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The overall progression-free survival (PFS) was 10.54 years.

2. Patients with body mass weight (BMI) ≥ 24 derived greater survival benefit from metformin plus epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), compared to EGFR-TKIs only.

Evidence Rating Level: 2 (Good)

Study Rundown: Recently, metformin has been associated with reducing the mortality of various cancers. Due to its anti-tumour properties, there have been interests in evaluating whether metformin improves the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatments in cancer patients. There have been several phase 2 trials with lack of consistent results due to variations of metformin doses used and the differences in patient demographics. Therefore, this post-hoc study of a phase 2 trial aimed to explore whether there is an association of body mass index (BMI) and the clinical benefits from metformin in patients with advanced lung adenocarcinoma receiving EGFR-TKIs. The improvement in progression-free survival (PFS) and overall survival (OS) from adding metformin to EGFR-TKIs was only seen in patients with BMI ≥ 24. Patients with BMI <24 did not show benefit for either PFS or OS. Limitations of the analyses include that this is a post hoc analysis, inability to include all patients from the initial trial that have incomplete data and the limited number of patients. Overall, this study demonstrated that BMI could be a key factor modulator of the effect of metformin and EGFR-TKIs for cancer therapy. However, further prospective investigation is required to confirm the association of BMI with metformin and EGFR-TKI synergy.

Click to read the study in JAMA Oncology

Relevant Reading: Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial

In-Depth [randomized controlled trial]: This was a post hoc analysis of a phase II study and included patients with epidermal growth factor receptor (EGFR) variant-positive non-small-cell lung cancer (NSCLC). Patients were randomized to receive EGFR-tyrosine kinase inhibitor (TKI) only or EGFR-TKI plus metformin. A total of 133 patients (mean age [SD]: 59.39 [13.07]) were included in the analysis. The overall progression-free survival (PFS) was 10.54 (95% confidence interval [CI]: 8.92-12.17). Patients with body mass weight (BMI) ≥ 24 showed statistically significant improvement in PFS from adding metformin to their EGFR-TKIs (15.83 months [95% CI: 9.93-21.73]), compared to EGFR-TKIs only (8.34 [95% CI: 6.09-10.59 months]). The corresponding hazard ratio was 0.4 (95% CI: 0.2-0.7, p=0.03). BMI ≥ 24 patients also showed improvement to OS from the addition of metformin to their EGFR-TKI therapy (31.44 [95% CI: 10.28-52.60 months]), compared to EGFR-TKIs only (18.00 [95% CI: 11.31-24.70 months). The corresponding hazard ratio was 0.55 (95% CI: 0.31-0.98, p=0.04). For patients with BMI <24, there was no statistically significant difference between metformin + TKI vs. TKI only (PFS p=0.65, OS p=0.68).

RELATED REPORTS

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: EGFR inhibitorlung cancermetformin
Previous Post

COVID-19 restrictions may improve sleep quality of narcolepsy and idiopathic hypersomnia patients

Next Post

Imatinib and binimetinib combination is a potential effective treatment for advanced gastrointestinal stromal tumours

RelatedReports

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Age and number of islet autoantibodies associated with diabetes risk
Oncology

The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers

May 16, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Next Post
Neuroendocrine tumor marker pancreastatin may be predictive of survival

Imatinib and binimetinib combination is a potential effective treatment for advanced gastrointestinal stromal tumours

[Physician Comment] The extent of C. difficile infections may not differ in light of immune status

Oral microbiome therapy reduced Clostridioides difficile recurrence

Transcatheter aortic valve replacement provides only minor benefit to quality of life

Secondary Antibiotic Prophylaxis Reduces Rheumatic Heart Disease Progression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.